Mocetinostat is primarily used in the field of oncology as a histone deacetylase (HDAC) inhibitor. It targets specific HDAC enzymes, which play a role in regulating gene expression, particularly in cancer cells. By inhibiting these enzymes, it helps to restore normal gene function and induce apoptosis in malignant cells. This makes it a potential therapeutic agent for treating various cancers, including lymphoma, leukemia, and solid tumors. It is often studied in clinical trials to evaluate its efficacy and safety in combination with other anticancer drugs or as a standalone treatment. Additionally, research explores its role in modulating the immune response, potentially enhancing the body’s ability to fight cancer.